Navigation Links
Analyst Available to Comment on New JUPITER Study That Shows AstraZeneca's Crestor Significantly Reduces CV Risk
Date:11/19/2008

WALTHAM, Mass., Nov. 19 /PRNewswire/ --Graeme GreenPh.D, analyst at Decision Resources, is available to discuss the results of the JUPITER study presented at the American Heart Association (AHA) Scientific Sessions this month.

The results of the 17,802-patient trial demonstrated AstraZeneca's Crestor to be effective at cutting the risk of heart attack and death among patients who seemed healthy but showed high levels of high-sensitivity C-reactive protein (hsCRP). In the study, those who had normal LDL cholesterol levels, but who were identified as being at increased cardiovascular risk due to elevated hsCRP, received either Crestor or placebo. Findings showed that those who took Crestor had a 44 percent reduction in the occurrence of a first major cardiovascular event and a 47 percent reduction in the combined risk of stroke, heart attack or cardiovascular death, compared with those who took placebo. The data also indicated that total mortality in the Crestor group was reduced by 20 percent versus the placebo group.

Dr. Green is available to discuss:

  • The initial reaction from thought leaders at the AHA in response to the JUPITER study
  • How the positive messaging and heightened patient awareness for Crestor after the JUPITER trial will boost sales of the brand in the near term
  • The potential for changes to Crestor's label, treatment guidelines and MCO reimbursement status, and how these changes will impact Crestor's revenue
  • The place of hsCRP testing in routine clinical practice
  • Crestor-specific effects vs. statin class effects

To speak with Dr. Green, please contact Heather Hilty at 781-296-2536 or hhilty@dresources.com.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Heather Hilty                       Elizabeth Marshall
    Decision Resources                  Decision Resources, Inc.
    781-296-2536                        781-296-2563
    hhilty@dresources.com               emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
2. AMN Healthcare Services to Host Analyst Day on Tuesday, September 18, 2007
3. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
4. Arbios Systems, Incs Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc.
5. Perrigo Company to Host Analyst Meeting on September 18, 2007
6. Sentillion Positioned in Visionaries Quadrant in Leading Industry Analyst Firms User Provisioning Magic Quadrant
7. Par Invites Public to Listen to Webcast of its September 28 Analysts Meeting
8. Par Pharmaceutical Provides Summary of Analyst/Investor Day
9. Accuray to Webcast Senior Management Presentations at Analyst Day Event
10. Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007
11. FBR Capital Markets Hires Senior Healthcare Analyst
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... Institute for Health and Care Excellence (NICE) framework. The agreement allows purchasers ... (NHS) to search, order and purchase medical and healthcare-related content through GOBI ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
(Date:2/23/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company ... the urology market, will release financial results for the ... before the market open on Thursday, March 9, 2017. ... call and webcast to discuss its financial results the ... a.m. Eastern Time (10:00 a.m. Central Time). Darin ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
Breaking Medicine Technology: